Results 31 to 40 of about 13,123 (252)

Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)

Journal of Gynecologic Oncology, 2022
Objective To investigate the health-related quality of life (HRQOL) related to hyperthermic intraperitoneal chemotherapy (HIPEC) following primary or interval cytoreductive surgery for primary ovarian cancer. Methods Between 2010 and 2016, a total of 184
J. Kim, Dong-eun Lee, Yumi Lee, H. I. Ha, Y. Chang, Suk-Joon Chang, Sang-Yoon Park, M. Lim   +7 more
semanticscholar   +1 more source

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study

Frontiers in Oncology, 2022
To evaluate the additive effects of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval debulking surgery (IDS) in patients with advanced-stage ovarian cancer.
Yong Jae Lee, Ki Eun Seon, Dae Chul Jung, Jung-Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim   +7 more
doaj   +1 more source

Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers

International Journal of Molecular Sciences, 2022
Most patients with epithelial ovarian cancers (EOCs) are at advanced stages (stage III–IV), for which the recurrence rate is high and the 5-year survival rate is low.
Pei-Qi Lim, I. Han, K. Seow, Kuo-Hu Chen
semanticscholar   +1 more source

Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?

Cancer Treatment and Research Communications, 2022
Introduction: The role of a molecular pattern predictive of hyperthermic intraperitoneal chemotherapy (HIPEC) efficacy in advanced ovarian cancer (AOC) patients has been poorly investigated.
Valentina Ghirardi, Francesca De Felice, Marco D'Indinosante, Federica Bernardini, Maria Teresa Giudice, Anna Fagotti, Giovanni Scambia   +6 more
doaj   +1 more source

HIPEC in Peritoneal Metastasis of Gastric Origin: A Systematic Review of Regimens and Techniques

Journal of Clinical Medicine, 2022
(1) Background: Peritoneal metastasis in gastric cancer is associated with a poor prognosis. Complete cytoreductive surgery including gastrectomy and complete removal of all peritoneal lesions followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Felix Gronau, Linda Feldbruegge, Frauke Oberwittler, S. González-Moreno, L. Villeneuve, C. Eveno, O. Glehen, S. Kusamura, B. Rau   +8 more
semanticscholar   +1 more source

The efficacy of traditional chinese medicine combined with hyperthermic intraperitoneal chemotherapy for malignant ascites: A systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Objective: Malignant ascites (MA) is a common complication of terminal cancer, which seriously affects the life quality and prognosis of patients. Both hyperthermic intraperitoneal chemotherapy (HIPEC) and traditional Chinese medicine (TCM) preparations ...
Zhixian Lin, Jiangfeng Chen, Yunxia Liu
doaj   +1 more source

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies

Journal of Clinical Medicine, 2022
Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery ...
Megan M Harper, Joseph J Kim, P. Pandalai   +2 more
semanticscholar   +1 more source

Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution

Molecules, 2020
Hyperthermic intraperitoneal chemoperfusion (HIPEC) is an established form of locoregional chemotherapy of peritoneum tumors. However, its efficacy and safety status remain a controversy, partially, due to scarce data on pharmacokinetics and toxicity ...
Galina Kireeva, Stepan Kruglov, Mikhail Maydin, Ekaterina Gubareva, Elena Fedoros, Ekaterina Zubakina, Natalya Ivanenko, Marina Bezruchko, Nikolay Solovyev   +8 more
doaj   +1 more source

Limitations of laparoscopy to assess the peritoneal cancer index and eligibility for cytoreductive surgery with HIPEC in peritoneal metastasis

Langenbeck's archives of surgery (Print), 2022
We aimed to determine the value of laparoscopy to assess the intra-abdominal tumor extent and predict complete cytoreduction. All patients at our department in the period from 2017 to 2021 that underwent laparoscopy to assess peritoneal metastasis and ...
C. Yurttas, L. Überrück, Giorgi Nadiradze, A. Königsrainer, P. Horvath   +4 more
semanticscholar   +1 more source

Assessment of Hyperthermic Intraperitoneal Chemotherapy to Eradicate Intraperitoneal Free Cancer Cells

Translational Oncology, 2016
OBJECTIVE: To assess the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) to eradicate intraperitoneal free cancer cells and to explore the feasibility of cytological cure for peritoneal carcinomatosis (PC).
Zhonghe Ji, Jianhua Sun, Haitao Wu, Qian Zhang, Kaiwen Peng, Yan Li   +5 more
doaj   +1 more source